Kura Oncology, Inc.
KURAKura Oncology, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for the treatment of cancer. The company's pipeline primarily includes small-molecule drugs designed to selectively inhibit specific proteins involved in cancer growth and progression. Based in San Diego, California, Kura aims to address unmet medical needs in oncology with precision medicines.
Company News
Multiple biotech companies are advancing innovative immunotherapy and targeted treatments for blood cancers, with significant clinical trial progress and FDA approvals in acute myeloid leukemia (AML) and related hematologic conditions.
Kura Oncology and Kyowa Kirin announced FDA approval of KOMZIFTI, a once-daily oral menin inhibitor for relapsed/refractory NPM1-mutated AML, which has been added to NCCN Guidelines as a recommended treatment option.
Kura Oncology presented preliminary clinical data at ESMO 2025 demonstrating promising results for its farnesyl transferase inhibitor (FTI) programs, showing potential in combination therapies for treating various cancer types with encouraging response rates.
Market report highlights emerging menin inhibitor drugs targeting high-risk acute leukemias, with over 15 drugs in clinical trials and potential market opportunity exceeding $400 million by 2028.
